Ondine Biomedical Inc. — Proxy Solicitation & Information Statement 2026

Jun 4, 2026

National Storage Mechanism | Additional information

RNS Number : 9124G

Ondine Biomedical Inc.

04 June 2026

4 June 2026

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Notice of AGM

Ondine Biomedical Inc. (AIM: OBI) announces that the notice of the Company's 2026 Annual General Meeting ("AGM") and the associated form of proxy have been published today on the Company's website at https://ondinebio.com/investors/reports-documentation/.

Printed copies of the notice of AGM and form of proxy will be posted today to registered shareholders who have elected to receive paper communications.

The Company's AGM will be held virtually at 16:00 BST (08:00 Pacific time) on 30 June 2026. Details of how to access the meeting are contained in the notice of AGM.

All shareholders are encouraged to submit their vote by proxy, well in advance of the meeting. Details of how to vote by proxy are contained in the notice of AGM. All valid proxy votes (whether submitted electronically or in hard copy form) will be included in the poll vote to be taken at the meeting.

The items of business to be voted on at the Meeting are:

·    the re-election of Carolyn Cross, Nicolas G. Loebel, Jean Charest, Jean Duvall, Junaid Bajwa, and Margaret Shaw as directors of the Company to hold office until the 2027 annual meeting of shareholders or until their successors are elected and qualified, subject to earlier resignation or removal.

·    the re-appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors for the Company for the ensuing year; and

·    to transact such other business as may properly come before the Meeting.

The result of the AGM will be announced after its conclusion and published on the Company's website.

**ENDS**

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications	+001 (604) 838 2702
Strand Hanson Limited (Nominated & Joint Financial Adviser)
James Harris, Richard Johnson	+44 (0)20 7409 3494
Peel Hunt LLP (Broker & Joint Financial Adviser)
James Steel, Dr. Chris Golden	+44 (0)20 7418 8900
5654 & Company (Financial PR and IR Adviser)	[email protected]
Matthew Neal, Chris Gardner, Melissa Gardiner	+44 0791 7800 011
	+44 0775 7697 357

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico, and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

U.S. Regulatory Status Disclaimer

Steriwave® is CE-marked in Europe and is approved for nasal decolonisation in Canada, the United Kingdom, Australia, and Mexico. In the United States, Steriwave has been granted Qualified Infectious Disease Product (QIDP) designation and Fast Track status by the U.S. Food and Drug Administration (FDA). It is currently undergoing clinical trials in the United States to support regulatory approval and is limited by United States law to investigational use only. It is not commercially available for sale or clinical use in the United States.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAUORWRNSUNRAR